This post was originally published on this site A qualitative study has proposed nine recommendations from breast cancer survivors about how to reduce the financial burden associated with the disease, which include changes to insurance, supportive services, financial assistance, and protective policies. The findings of the study, “Patient recommendations for reducing long‐lasting economic burden after…
Conditions
Conditions
FDA Delays Decision on Selinexor’s Approval for Heavily Treated Multiple Myeloma
This post was originally published on this site The U.S. Food and Drug Administration is delaying its decision on a new drug application (NDA) seeking approval of selinexor in combination with dexamethasone for patients with multiple myeloma who failed at least three prior therapies. This means that the FDA will decide whether to approve the oral…
Targazyme Gets Funding for Trial Testing TZ101 for Erectile Dysfunction in PC Patients
This post was originally published on this site Targazyme has been granted an award from the The Sexual Medicine Society of North America that will fund a clinical trial testing the company’s stem cell-based product TZ101 to reverse erectile dysfunction in prostate cancer patients. The study will be conducted at The University of Texas Health…
Doc, You’re a Downer. Let Me Revel in My 5-Year Mark
This post was originally published on this site I met a guy at a party. At first, he was quite the charmer, one of those middle-aged guys who was the most popular guy in high school. Standing within his orbit, I felt like I’d been invited to join the cool kids’ cafeteria table and everyone…
INB03 May Help Reverse Cancer’s Resistance to Immunotherapy, INmune Bio Co-founder Says
This post was originally published on this site Therapy candidate INB03, meant to inactivate a kind immunosuppressive cell called myeloid-derived suppressor cells (MDSCs) while boosting anti-tumor immune cells, may help overcome resistance to immunotherapies, including immune checkpoint inhibitors, INmune Bio’s co-founder Raymond J. Tesi, MD, said at a conference. Tesi, CEO of INmune Bio, presented the potentialities…
Leukemia & Lymphoma Society’s Silicon Valley Chapter Raises $297K in ‘Student of the Year’ Contest
This post was originally published on this site The Leukemia & Lymphoma Society’s (LLS) Silicon Valley Student of the Year drive netted more than $297,000 to support the organization’s research and patient support efforts. Funds were raised through the LLS’ Silicon Valley & Monterey Bay Area chapter by some 39 high school students. The top fundraisers were Evergreen…
UB-311 Vaccine Safe in Mild Alzheimer’s Patients, Phase 2a Trial Shows
This post was originally published on this site United Neuroscience’s vaccine candidate UB-311 was safe and well-tolerated in patients with mild Alzheimer’s disease, according to results from a Phase 2a clinical trial. Patients who participated in this trial are now eligible to enroll in a long-term follow-up study that will continue to assess the vaccine’s safety…
FDA Proposes New Policies to Modernize, Improve Quality of Mammography Screenings
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has proposed a set of new policies to modernize and improve the quality of mammography screenings for breast cancer. The federal agency is confident that such measures may help women facing the disease make informed decisions about their health care.…
Phase 1 Study Begins Dosing High-Grade Glioma Patients with GMCI Combo Therapy
This post was originally published on this site A Phase 1 study has started dosing patients who have newly diagnosed high-grade gliomas with a combination of Candel Therapeutics‘ gene-mediated cytotoxic immunotherapy (GMCI) plus Opdivo (nivolumab) and standard of care therapy. GMCI (aglatimagene besadenovec plus prodrug) is an “off-the-shelf” adenovirus-based medicine meant to increase the amount…
European Panel OKs Approval of Triple Combination Therapies for Multiple Myeloma Patients
This post was originally published on this site The European Medicines Agency‘s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Celgene‘s Revlimid (lenalidomide) and Pomalyst (pomalidomide, marketed as Imnovid in Europe) as combination therapies with Velcade (bortezomib) and dexamethasone for adult patients with multiple myeloma. In the case of Revlimid, the triple…
DPX-Survivac Treatment Continues to Show Promise in Women with Advanced Ovarian Cancer, Early Data Show
This post was originally published on this site Treatment with DPX-Survivac plus intermittent low-dose cyclophosphamide continues to show promise in women with advanced recurrent ovarian cancer, the second part of a Phase 1/2 trial shows. Interim data from the first six patients revealed that five patients (83%) achieved stable disease, including two tumor regressions —…
Radioactive Compound Shows Promise as Therapy for Metastatic Castration-resistant Prostate Cancer Patients
This post was originally published on this site Treatment with the radioactive molecule lutetium-177-PSMA-617 (LuPSMA), which binds to the prostate-specific membrane antigen, is a potential therapeutic strategy for patients with metastatic castration-resistant prostate cancer (CRPC), results from a pilot study suggest. The findings were shared in the poster, “Results of a 50 patient single-centre phase…